Protein-losing enteropathy after the fontan operation: An international multicenter study

被引:351
作者
Mertens, L
Hagler, DJ
Sauer, U
Somerville, J
Gewillig, M
机构
[1] UZ Leuven, Dept Pediat Cardiol, Leuven, Belgium
[2] Mayo Clin & Mayo Fdn, Dept Pediat Cardiol, Rochester, MN 55905 USA
[3] Deutsch Herzzentrum, Munich, Germany
[4] Royal Brompton & Natl Heart Hosp, Grown Congenital Heart Unit, London, England
关键词
D O I
10.1016/S0022-5223(98)70406-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This multicenter study retrospectively analyzes the data on 114 patients with protein-losing enteropathy after Fontan-type surgery, Special attention was given to the different treatment strategies used and their effect on outcome. Methods and results: In 35 participating centers 3029 Fontan operations were performed. The incidence of protein-losing enteropathy in the survivors was 3.7%. The median age at Fontan-type surgery was 8.2 years (range: 0.6 to 32.9 years). Median age at diagnosis of protein-losing enteropathy was 11.7 years with a median time interval between surgery and diagnosis of 2.7 years (range: 0.1 to 16.4 years). Most patients had edema (79%) and effusions (75%). Hemodynamic data revealed a mean right atrial pressure of 17 +/- SD 5.3 mm kg with a cardiac index, of 2.4 +/- 0.8 L/min/m(2). Medical treatment only (n = 52) resulted in a complete resolution of symptoms in 25%, no improvement in 29%, and death in 46%. Surgical treatment (n = 52) was associated with relief of protein-losing enteropathy in 19%, no improvement in 19%, and death in 62%. In 13 patients 16 percutaneous interventions were performed. This resulted in symptomatic improvement after 12 interventions and no improvement after 4 interventions. Conclusions: We conclude that the current treatment of protein-losing enteropathy after Fontan operation is associated with a very high mortality and morbidity rate. Preventive strategies and new therapeutic approaches are necessary.
引用
收藏
页码:1063 / 1073
页数:11
相关论文
共 25 条
[1]   Improved early morbidity and mortality after fontan operation: The Mayo Clinic experience, 1987 to 1992 [J].
Cetta, F ;
Feldt, RH ;
OLeary, PW ;
Mair, DD ;
Warnes, CA ;
Driscoll, DJ ;
Hagler, DJ ;
Porter, CJ ;
Offord, KP ;
Schaff, HV ;
Puga, FJ ;
Danielson, GK .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 28 (02) :480-486
[2]   PROTEIN-LOSING ENTEROPATHY AFTER FONTAN OPERATION FOR TRICUSPID ATRESIA (IMPERFORATE TRICUSPID-VALVE) [J].
CRUPI, G ;
LOCATELLI, G ;
TIRABOSCHI, R ;
VILLANI, M ;
DETOMMASI, M ;
PARENZAN, L .
THORACIC AND CARDIOVASCULAR SURGEON, 1980, 28 (05) :359-363
[3]  
DAVIDSON JD, 1961, LANCET, V1, P899
[4]   ENTERIC PROTEIN LOSS AFTER THE FONTAN OPERATION [J].
DAVIS, CA ;
DRISCOLL, DJ ;
PERRAULT, J ;
GREENWOOD, DH ;
SCHAFF, HV ;
PUGA, FJ ;
DANIELSON, GK ;
FELDT, RH .
MAYO CLINIC PROCEEDINGS, 1994, 69 (02) :112-114
[5]   Use of computational fluid dynamics in the design of surgical procedures: Application to the study of competitive flows in cavopulmonary connections [J].
deLeval, MR ;
Dubini, G ;
Migliavacca, F ;
Jalali, H ;
Camporini, G ;
Redington, A ;
Pietrabissa, R .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 111 (03) :502-510
[6]  
DELEVAL MR, 1988, J THORAC CARDIOV SUR, V96, P682
[7]   Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation [J].
Donnelly, JP ;
Rosenthal, A ;
Castle, VP ;
Holmes, RD .
JOURNAL OF PEDIATRICS, 1997, 130 (03) :474-478
[8]  
FELDT R, 1995, J THORAC CARDIOVASC, V112, P672
[9]  
GEWILLIG M, 1995, EUR J CARDIAC INTERV, V4, P122
[10]  
GLEASON WA, 1979, J THORAC CARDIOV SUR, V77, P843